This review offers a summary of current evidence pertaining to hormone replacement using GH, thyroid hormone and sex hormones in CCS and their potential association with tumor progression or recurrence as well as the risk for subsequent neoplasms in order to facilitate patient counseling and treatment decisions. The gene discussed is GH1; the disease is neoplasm.